COHERUS BIOSCIENCES Inc., NASDAQ:CHRS, is a bioscience company that has not yet not benefited from the sector's outperformance despite significantly improving financials and the business becoming profitable. When the stock price cracks the $21 level it will unlock a significant bullish potential.